Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (ASAP1, also commonly known as AMAP1) is a multidomain ADP-ribosylation factor (Arf) GTPase-activating protein (GAP) that plays a pivotal role in regulating membrane trafficking, receptor recycling, and actin cytoskeleton remodeling. It possesses GAP activity stimulated by phosphatidylinositol 4,5-bisphosphate (PIP2), primarily targeting ARF1 and ARF5, and to a lesser extent ARF6. In cancer, AMAP1 is frequently overexpressed and acts as a critical downstream effector of the ARF6 pathway, where it forms a trimeric complex with cortactin and paxillin at invadopodia to drive extracellular matrix degradation, tumor cell invasion, and metastasis. Additionally, AMAP1 regulates the recycling of integrins and immune checkpoint proteins like PD-L1, contributing to immune evasion and drug resistance in various malignancies, including breast, pancreatic, and lung cancers. Pharmacological targeting of AMAP1 has been explored using small-molecule inhibitors like the broad-spectrum ARFGAP inhibitor QS11, the SH3-domain blocker UCS15A, and cell-permeable peptidomimetics like P4-TAT, which disrupt its interaction with cortactin to suppress metastatic progression.
Inhibition of ARFGAP catalytic activity or disruption of atypical protein-protein interactions (such as AMAP1-cortactin or AMAP1-CIN85 binding) to block downstream signaling, receptor recycling, and cytoskeletal remodeling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (ASAP1).